Showing 1311-1320 of 5603 results for "".
The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
https://reachmd.com/programs/cme/the-new-era-of-ras-targeting-mechanisms-evidence-and-clinical-integration-of-on-state-inhibitors/39770/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
https://reachmd.com/programs/cme/evaluating-use-in-pancreatic-cancer-efficacy-and-safety-data-for-on-state-ras-inhibitors/54122/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.The Future of Oral SERDs: Combination Strategies
https://reachmd.com/programs/cme/the-future-of-oral-serds-combination-strategies/39801/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Spotlight on Europe: Adapting the Evidence
https://reachmd.com/programs/cme/spotlight-on-europe-adapting-the-evidence/39808/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Case Review: Targets Are Met—Can You Stick the Landing?
https://reachmd.com/programs/cme/case-review-targets-are-metcan-you-stick-the-landing/51488/Explore IBD from diagnosis to remission with practical cases, treatment strategies, and a treat-to-target approach for optimal patient outcomes.Do Not Delay: Timing, Triggers, and Identifying the Right Patient for Additional Therapies in HFrEF
https://reachmd.com/programs/cme/do-not-delay-timing-triggers-and-identifying-the-right-patient-for-additional-therapies-in-hfref/54633/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
https://reachmd.com/programs/cme/redefining-ohcm-care-efficacy-and-safety-of-myosin-inhibitors/54840/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
https://reachmd.com/programs/cme/from-evidence-to-action-integrating-emerging-myosin-inhibitors-into-ohcm-treatment-plans/54841/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Treating MASH With Compensated Cirrhosis: A Serious Unmet Need
https://reachmd.com/programs/cme/treating-mash-with-compensated-cirrhosis-a-serious-unmet-need/37646/Do you know how to optimally manage MASH with compensated cirrhosis? Watch Dr. Alkhouri discuss expert guidance and new data in this case-based discussion.When ß-Blockers Fall Short in oHCM: Time for a New Approach?
https://reachmd.com/programs/cme/when-blockers-fall-short-in-ohcm-time-for-a-new-approach/54838/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.